Health TrialsbyHealthPanel

HLA B Leader in Patients With Psoriatic Arthritis

ConditionsPsoriatic ArthritisHLA b LeaderHLA B27
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorCentre Hospitalier Universitaire, Amiens

About this trial

Psoriatic arthritis (PsA), a chronic immune-mediated heterogeneous inflammatory disease characterized by musculoskeletal inflammation (arthritis, enthesitis, spondylitis and dactylitis), usually occurs in patients with psoriasis. The spondyloarthritides (SPs) (of which psoriasis is one) are a group of inflammatory diseases that share an association with the HLA-B27 MHC class I molecule.

Given this association, these diseases are classically regarded as disorders of adaptive immunity.

In bone marrow donation, HLA-B exon 1 dimorphism (HLAB leader) is associated with risk of graft- versus-host disease, relapse and overall survival after unrelated hematopoietic cell transplantation (UHCT), haploidentical UHCT and cord transplantation. In the literature, there are no studies suggesting the involvement of the HLA B leader gene in MS and RPs. The main aim of this study is to compare the presence of the HLA B leader gene between a group of patients with psoriatic arthritis and a healthy group without inflammatory disease.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patient over 18 years of age

Patient affiliated to a social security scheme

Patient with psoriatic arthritis according to the CASPAR 2006 classification, followed at the CHU Amiens-Picardie.

Individuals over 18 years of age

Disqualifiers

Patient or control not understanding French

Patient not included in the Amiens Picardie University Hospital's "Psoriatic Rheumatism" cohort, or control not included in the Amiens Picardie University Hospital's bone marrow donor cohort.

Patient or control objecting to participation in the study

Trial design

Design model

Parallel

Treatments tested in this trial

  • blood test

    Biological/Vaccine

    Addition of an extra tube for blood tests (a single tube for genetic research), enabling phenotyping of the HLA B27 and HLA B leader genes.

Treatment groups

658 Participants
are divided into 2 treatment groups
Group A: psoriatic rheumatism patientExperimental treatment 1 intervention
Group B: healthy groupActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

prevalence of HLA B leader in both groups

prevalence of HLA B leader in patients with psoriatic rheumatism compared to the healthy group by autoimmune disease

Time frame
1 year

Secondary outcomes

1

Prevalence of HLAB27 gene in both groups

Prevalence of HLAB27 gene in patients with psoriatic rheumatism compared to the healthy group free from autoimmune disease

Time frame
1 year
2

prevalence of the HLAB27/ HLA b Leader gene in different forms of psoriatic rheumatism patient group

prevalence of the HLAB27/ HLA b Leader gene in different forms of psoriatic rheumatism in patients with different disease conditions

Time frame
1 year

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Centre Hospitalier Universitaire, Amiens

Lead sponsor

Source ClinicalTrials.gov
Apply now